Xeljanz approved for rheumatoid arthritis
November 7, 2012 in Arthritis & Rheumatism
(HealthDay)—Xeljanz (tofacitinib) has been approved by the U.S. Food and Drug Administration to treat symptoms of rheumatoid arthritis (RA) among people who can't tolerate, or haven't been helped by, the drug methotrexate.
RA is an autoimmune disease in which the immune system mistakenly attacks the body. In the case of RA, this leads to swelling of the joints and nearby tissues. About 1.5 million Americans have RA, the FDA said in a news release.
A twice-daily pill, Xeljanz is designed to block molecules involved in joint inflammation, the FDA said.
The drug was evaluated in seven clinical studies of adults with moderate-to-severe RA. The drug carries a "black box" label warning of an increased risk of infection triggered by a suppressed immune system, and tuberculosis and certain cancers.
Other serious side effects could include increased cholesterol levels and liver enzyme problems, the FDA said. More common adverse reactions were upper respiratory tract infections, headaches, diarrhea and nasal inflammation.
Xeljanz is marketed by New York-based Pfizer Inc.
More information: The U.S. National Library of Medicine has more about rheumatoid arthritis.
Copyright © 2012 HealthDay. All rights reserved.
-
FDA panel urges approval for Pfizer arthritis drug
May 09, 2012 |
not rated yet |
0
-
Steroids prevent protein changes seen in the joints of people with rheumatoid arthritis
Jan 27, 2012 |
not rated yet |
0
-
Pfizer says patient died in oral RA drug study
Apr 22, 2011 |
not rated yet |
0
-
Study shows efficacy of new rheumatoid arthritis drug
Aug 09, 2012 |
not rated yet |
0
-
New biologic drug is effective against rheumatoid arthritis
Oct 06, 2009 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Rotating electron as a dipole is this right?
1 hour ago
-
Dipole term in multipole expansion
5 hours ago
-
Bubbles in a Pre-Boiling/Boiling pot of water
6 hours ago
-
Assumptions of Griffith's fracture theory
17 hours ago
-
Current leading voltage or vice versa concept
18 hours ago
-
Angular Frequency of AC voltage
22 hours ago
- More from Physics Forums - Classical Physics
More news stories
Sugar injections for knee arthritis may ease pain
(HealthDay)—Injections of a sugar solution appear to help relieve knee pain and stiffness related to osteoarthritis, a new study suggests.
Arthritis & Rheumatism
12 hours ago |
4 / 5 (1) |
0
|
Blame your parents for bunion woes
A novel study reports that white men and women of European descent inherit common foot disorders, such as bunions (hallux valgus) and lesser toe deformities, including hammer or claw toe. Findings from the Framingham Foot ...
Arthritis & Rheumatism
May 20, 2013 |
not rated yet |
0
|
New theory on genesis of osteoarthritis comes with successful therapy in mice
Scientists at Johns Hopkins have turned their view of osteoarthritis (OA) inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, ...
Arthritis & Rheumatism
May 19, 2013 |
4.9 / 5 (7) |
0
|
Ultrasound findings can improve classification of RA
(HealthDay)—Compared to clinical diagnosis of synovitis, ultrasound-detected synovitis provides either improved sensitivity or specificity when used with the American College of Rheumatology/European League ...
Arthritis & Rheumatism
May 15, 2013 |
not rated yet |
0
Discovery shows fat triggers rheumatoid arthritis
Scientists have discovered that fat cells in the knee secrete a protein linked to arthritis, a finding that paves the way for new gene therapies that could offer relief and mobility to millions worldwide.
Arthritis & Rheumatism
May 08, 2013 |
5 / 5 (5) |
0
|
New sleeping pill poised to hit US markets
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
If you can remember it, you can remember it wrong
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
Reducing caloric intake delays nerve cell loss
Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...
B vitamins could delay dementia
(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...
Antidepressant reduces stress-induced heart condition
A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.
Changing cancer's environment to halt its spread
By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...
